Literature DB >> 22428778

Presentation and validation of the multiple sclerosis depression rating scale: a test specifically devised to investigate affective disorders in multiple sclerosis patients.

Davide Quaranta1, Camillo Marra, Massimiliano Zinno, Agata Katia Patanella, Maria Josè Messina, Chiara Piccininni, Anna Paola Batocchi, Guido Gainotti.   

Abstract

Accurate diagnosis of depression in patients affected by MS is important, as it may be a cause of reduced quality of life and increased suicide risk. We present a new scale, the Multiple Sclerosis Depression Rating Scale (MSDRS), and assess its diagnostic accuracy in comparison to the Beck Depression Inventory (BDI). A total of 94 MS participants were classified as non-depressed (N = 44) or affected by mood disorder associated to MS with depressive manifestations (MSD-MDDM; N = 37) or with a major depression-like episode (MSD-MDL; N = 13). Each participant underwent a psychiatric interview, MSDRS, and BDI; diagnostic accuracy was evaluated using area under the ROC curve (AROC). The diagnostic accuracy of MSDRS and BDI was comparable when diagnosing both MSD-MDDM and MSD-MDL (AROC respectively 0.8998 and 0.8659); the MSDRS showed higher accuracy for the diagnosis of MSD-MDL (AROC respectively 0.9278 and 0.8314; p = .038). The MSDRS may be a reliable tool for the diagnosis of depression in MS.

Entities:  

Mesh:

Year:  2012        PMID: 22428778     DOI: 10.1080/13854046.2012.668220

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  4 in total

1.  Validation of mood measures for people with multiple sclerosis.

Authors:  Tessa M Watson; Emma Ford; Esme Worthington; Nadina B Lincoln
Journal:  Int J MS Care       Date:  2014

Review 2.  Psychiatric disorders in multiple sclerosis.

Authors:  Maddalena Sparaco; Luigi Lavorgna; Simona Bonavita
Journal:  J Neurol       Date:  2019-06-13       Impact factor: 4.849

3.  Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires.

Authors:  Anja Fischer; Marcus Fischer; Robert A Nicholls; Stephanie Lau; Jana Poettgen; Kostas Patas; Christoph Heesen; Stefan M Gold
Journal:  Brain Behav       Date:  2015-07-14       Impact factor: 2.708

4.  Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial.

Authors:  Carlo Pozzilli; Luca Prosperini; Silvia Tommasin; Claudio Gasperini; Elena Barbuti; Laura De Giglio
Journal:  Ther Adv Neurol Disord       Date:  2021-04-24       Impact factor: 6.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.